JP6998866B2 - 緑膿菌ＰｃｒＶ連結型抗原ワクチン - Google Patents

緑膿菌ＰｃｒＶ連結型抗原ワクチン Download PDF

Info

Publication number
JP6998866B2
JP6998866B2 JP2018520162A JP2018520162A JP6998866B2 JP 6998866 B2 JP6998866 B2 JP 6998866B2 JP 2018520162 A JP2018520162 A JP 2018520162A JP 2018520162 A JP2018520162 A JP 2018520162A JP 6998866 B2 JP6998866 B2 JP 6998866B2
Authority
JP
Japan
Prior art keywords
seq
pcrv
amino acid
protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018520162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535207A5 (enExample
JP2018535207A (ja
Inventor
マリー－ポール シモーヌ ジャンヌ フェロン，クリスティアーヌ
ヨッヘン ケムラー，ステファン
トーマス コワリク，ミヒャエル
ローラン ケバッテ，ジュリアン
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2018535207A publication Critical patent/JP2018535207A/ja
Publication of JP2018535207A5 publication Critical patent/JP2018535207A5/ja
Application granted granted Critical
Publication of JP6998866B2 publication Critical patent/JP6998866B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1014—Hydroxymethyl-, formyl-transferases (2.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/02—Hydroxymethyl-, formyl- and related transferases (2.1.2)
    • C12Y201/02002—Phosphoribosylglycinamide formyltransferase (2.1.2.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01019—Cyclomaltodextrin glucanotransferase (2.4.1.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018520162A 2015-10-21 2016-10-19 緑膿菌ＰｃｒＶ連結型抗原ワクチン Expired - Fee Related JP6998866B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1518668.7A GB201518668D0 (en) 2015-10-21 2015-10-21 Immunogenic Comosition
GB1518668.7 2015-10-21
PCT/EP2016/075048 WO2017067964A1 (en) 2015-10-21 2016-10-19 P. aeruginosa pcrv-linked antigen vaccines

Publications (3)

Publication Number Publication Date
JP2018535207A JP2018535207A (ja) 2018-11-29
JP2018535207A5 JP2018535207A5 (enExample) 2019-09-26
JP6998866B2 true JP6998866B2 (ja) 2022-02-04

Family

ID=55131414

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018520162A Expired - Fee Related JP6998866B2 (ja) 2015-10-21 2016-10-19 緑膿菌ＰｃｒＶ連結型抗原ワクチン

Country Status (10)

Country Link
US (1) US11406696B2 (enExample)
EP (1) EP3365004A1 (enExample)
JP (1) JP6998866B2 (enExample)
CN (1) CN108778322B (enExample)
BE (1) BE1024361B1 (enExample)
BR (1) BR112018007960A2 (enExample)
CA (1) CA3002117A1 (enExample)
GB (1) GB201518668D0 (enExample)
MX (1) MX2018004938A (enExample)
WO (1) WO2017067964A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7551618B2 (ja) 2018-12-12 2024-09-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
CA3128027A1 (en) * 2019-01-29 2020-08-06 Shire-Nps Pharmaceuticals, Inc. Parathyroid hormone variants
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
UY38616A (es) 2019-03-18 2020-09-30 Janssen Pharmaceuticals Inc Bioconjugados de polisacáridos del antígeno-o de e. coli y métodos de producción y de uso de los mismos.
EP3770269A1 (en) * 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
US11167019B2 (en) * 2019-12-13 2021-11-09 Albany Medical College Self-adjuvanting yersinia outer membrane vesicle as a vaccine against plague, anthrax and pseudomonas infection
CN111019000B (zh) * 2019-12-28 2023-03-28 重庆艾力彼生物科技有限公司 铜绿假单胞菌疫苗重组蛋白reFPO及制备方法和应用
US20230241197A1 (en) * 2020-05-27 2023-08-03 Kyoto Prefectural Public University Corporation Protein molecule useful for anti-pseudomonas aeruginosa vaccine
EP4168040A1 (en) 2020-06-18 2023-04-26 GlaxoSmithKline Biologicals S.A. Shigella-tetravalent (shigella4v) bioconjugate
IL301248B2 (en) 2020-09-17 2024-04-01 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
WO2022214620A1 (en) 2021-04-08 2022-10-13 Janssen Pharmaceuticals, Inc. Process for bioconjugate production
WO2023236041A1 (zh) * 2022-06-07 2023-12-14 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539743A (ja) 2005-05-11 2008-11-20 アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ 原核細胞由来の組み換えｎ−グリコシル化タンパク質
JP2011514155A (ja) 2008-02-20 2011-05-06 グリコヴァキシン アーゲー 原核細胞由来の組換えｎ−グリコシル化タンパク質から作製したバイオコンジュゲート
JP2015533511A (ja) 2012-11-07 2015-11-26 グリコヴァキシン アーゲー 酵素的コンジュゲート化による大腸菌での組み換えワクチンの製造
JP2017513480A (ja) 2014-04-17 2017-06-01 グリコヴァキシン アーゲー 改変型宿主細胞およびその使用
JP2017523794A (ja) 2014-08-08 2017-08-24 グリコヴァキシン アーゲー バイオコンジュゲート生成において使用するための改変型宿主細胞

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
SK279188B6 (sk) 1992-06-25 1998-07-08 Smithkline Beecham Biologicals S.A. Vakcínová kompozícia spôsob jej prípravy a použiti
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
EP0717106B1 (en) 1994-12-16 2000-03-15 Chiron Behring Gmbh & Co. Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
KR100947757B1 (ko) 2001-01-23 2010-03-18 아벤티스 파스퇴르 다가 수막구균 폴리사카라이드―단백질 접합체 백신
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
JP2008133206A (ja) * 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
EP2248826B1 (en) * 2008-01-10 2013-06-12 Shionogi&Co., Ltd. Antibody directed against pcrv
KR20110009158A (ko) 2008-04-16 2011-01-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
CA2720961A1 (en) 2008-04-16 2009-10-22 William Ripley Ballou, Jr. Streptococcus pneumonia vaccine
CN102341496B (zh) * 2009-03-11 2014-07-02 盐野义制药株式会社 具有抗绿脓杆菌作用的人源化PcrV抗体
CN101559222A (zh) * 2009-05-31 2009-10-21 北京绿竹生物制药有限公司 人用细菌多糖-蛋白结合联合疫苗
WO2011062615A1 (en) 2009-11-19 2011-05-26 Glycovaxyn Ag Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
JP6339366B2 (ja) 2010-05-06 2018-06-06 グリコヴァキシン アーゲー 莢膜グラム陽性菌のバイオコンジュゲートワクチン
LT2718320T (lt) * 2011-06-10 2018-04-10 Medimmune Limited Anti-pseodomonas psl surišančios molekulės ir jų panaudojimas
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
SG11201404532XA (en) * 2012-03-02 2014-08-28 Ablynx Nv Pseudomonas aeruginosa pcrv binding single variable domain antibodies
EP2906681B1 (en) 2012-10-12 2019-01-09 GlaxoSmithKline Biologicals S.A. Methods of host cell modification

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539743A (ja) 2005-05-11 2008-11-20 アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ 原核細胞由来の組み換えｎ−グリコシル化タンパク質
JP2011514155A (ja) 2008-02-20 2011-05-06 グリコヴァキシン アーゲー 原核細胞由来の組換えｎ−グリコシル化タンパク質から作製したバイオコンジュゲート
JP2015533511A (ja) 2012-11-07 2015-11-26 グリコヴァキシン アーゲー 酵素的コンジュゲート化による大腸菌での組み換えワクチンの製造
JP2017513480A (ja) 2014-04-17 2017-06-01 グリコヴァキシン アーゲー 改変型宿主細胞およびその使用
JP2017523794A (ja) 2014-08-08 2017-08-24 グリコヴァキシン アーゲー バイオコンジュゲート生成において使用するための改変型宿主細胞

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GREGORY P PRIEBE，VACCINES FOR PSEUDOMONAS AERUGINOSA : A LONG AND WINDING ROAD，EXPERT REVIEW OF VACCINES，英国，2014年04月25日，VOL:13, NR:4，PAGE(S):1 - 23 (507 - 519)，https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521563/pdf/nihms710058.pdf，http://dx.doi.org/10.1586/14760584.2014.890053
ISAR DEJBAN GOLPASHA et al，Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa，BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES，2015年03月，Vol. 15, No.2，p. 15-24

Also Published As

Publication number Publication date
BE1024361B1 (fr) 2018-02-05
CN108778322A (zh) 2018-11-09
EP3365004A1 (en) 2018-08-29
WO2017067964A1 (en) 2017-04-27
MX2018004938A (es) 2018-07-06
US20190091319A1 (en) 2019-03-28
BE1024361A1 (fr) 2018-01-30
CA3002117A1 (en) 2017-04-27
BR112018007960A2 (pt) 2018-10-30
US11406696B2 (en) 2022-08-09
JP2018535207A (ja) 2018-11-29
CN108778322B (zh) 2023-06-23
GB201518668D0 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
JP6998866B2 (ja) 緑膿菌ＰｃｒＶ連結型抗原ワクチン
JP6682451B2 (ja) 改変型宿主細胞およびその使用
BE1024767B1 (fr) Composition immunogene
US20230293657A1 (en) Vaccine
KR20150054800A (ko) 변형된 항원을 포함하는 생체접합체 및 이의 용도
CN115803087A (zh) 多价疫苗组合物及其用途
US20240139304A1 (en) P aeruginosa pcrv-linked antigen vaccines
US20240207383A1 (en) Minimal Sequons Sufficient for O-Linking Glycosylation
US20250381257A1 (en) Vaccine
WO2024175620A1 (en) Immunogenic composition
CN120897997A (zh) 用于生产具有与第二多肽配偶体的异肽键的糖缀合物多肽的组合物和方法以及这些糖缀合物多肽的用途

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20180618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210624

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211221

R150 Certificate of patent or registration of utility model

Ref document number: 6998866

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees